Shots:

• The EMA's CHMP adopted positive opinion recommending Prevymis (letermovir) for CMV prophylaxis in high-risk adult kidney transplant recipients & extends its dosing from 100 to 200 days for bone marrow transplant pts who are at risk for late CMV infection. EC’s final decision is expected by YE 2023
• The opinion regarding use of prevymis as CMV disease prophylaxis was based on P-III trial (NCT03443869) having 567 high risk adult kidney transplant recipients. Additionally, the opinion of extending Prevymis dosing from 14 wks. to 28 wks. post HSCT was based on another P-III trial (NCT03930615)
• Prevymis is an antiviral agent already approved by FDA for CMV disease prophylaxis in high-risk adult kidney transplant pts. and has extended 200-day dosing as CMV prophylaxis in HSCT recipients

Ref: Merck | Image: Merck

Related News:- Merck’s Prevymis (letermovir) Receives the US FDA’s Approval for Prevention of Cytomegalovirus Disease

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com